Journal ArticleDOI
Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells
Andrea Harrer,Peter Wipfler,Max Einhaeupl,Georg Pilz,Katrin Oppermann,Wolfgang Hitzl,Shahrzad Afazel,Elisabeth Haschke-Becher,Peter Strasser,Eugen Trinka,Joerg Kraus +10 more
Reads0
Chats0
TLDR
Expectedly, detectability of natalizumab-blocked alpha-4 was diminished on all investigated cell subsets, and a concurrent and significant decrease of beta-1 surface levels on T-cells, B- cells, natural killer cells, and natural killer T cells, but not on monocytes is reported.About:
This article is published in Journal of Neuroimmunology.The article was published on 2011-05-01. It has received 29 citations till now. The article focuses on the topics: Natalizumab & Natural killer T cell.read more
Citations
More filters
Journal ArticleDOI
l-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
Nicholas Schwab,Tilman Schneider-Hohendorf,Vilmos Posevitz,Johanna Breuer,Kerstin Göbel,Susanne Windhagen,Bruno Brochet,Patrick Vermersch,Christine Lebrun-Frenay,Anita Posevitz-Fejfar,Ruggero Capra,Luisa Imberti,Vera Straeten,Juergen Haas,Brigitte Wildemann,Joachim Havla,Tania Kümpfel,Ingrid Meinl,Kyle Niessen,Susan Goelz,Christoph Kleinschnitz,Clemens Warnke,Dorothea Buck,Ralf Gold,Bernd C. Kieseier,Sven G. Meuth,John Foley,Andrew T. Chan,David Brassat,Heinz Wiendl +29 more
TL;DR: The cell-based assessment of the percentage of l-selectin-expressing CD4 T cells could provide an urgently needed biomarker for individual PML risk assessment.
Journal ArticleDOI
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF
Clemens Warnke,Mark Stettner,Vera Lehmensiek,Thomas Dehmel,Anne K. Mausberg,Gloria von Geldern,Ralf Gold,Tania Kümpfel,Reinhard Hohlfeld,Mathias Mäurer,Martin Stangel,Vera Straeten,Volker Limmroth,Thomas Weber,Christoph Kleinschnitz,Mike P. Wattjes,Anders Svenningsson,Tomas Olsson,Hans-Peter Hartung,Derik Hermsen,Hayrettin Tumani,Ortwin Adams,Bernd C. Kieseier +22 more
TL;DR: Natalizumab impacts B and T cell distribution and exerts an inhibitory effect on surrogates of B cell function in periphery and in cerebrospinal fluid, potentially contributing to the increased risk of developing PML.
Journal ArticleDOI
Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Tatiana Plavina,Kumar Kandadi Muralidharan,Geoffrey Kuesters,Daniel D. Mikol,Karleyton C. Evans,Meena Subramanyam,Ivan Nestorov,Yi Chen,Qunming Dong,Pei Ran Ho,Diogo Amarante,Alison Adams,Jérôme De Seze,RJ Fox,Ralf Gold,Douglas Jeffery,L Kappos,Xavier Montalban,Bianca Weinstock-Guttman,Hans-Peter Hartung,Bruce A.C. Cree +20 more
TL;DR: Natalizumab's effects on peripheral immune cells and pharmacodynamic markers were reversible, with changes starting 8 weeks post last natalIZumab dose; levels returned to those observed/expected in untreated patients ≈16 weeks after last dose.
Journal ArticleDOI
Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.
Kathy Khoy,Delphine Mariotte,Gilles Defer,Gilles Defer,Gautier Petit,Olivier Toutirais,Olivier Toutirais,Brigitte Le Mauff,Brigitte Le Mauff +8 more
TL;DR: Mechanisms of action involved in therapeutic efficacy as well as in PML risk will be discussed, and the interest of a biological monitoring that may be helpful to rapidly adapt treatment is presented.
Journal ArticleDOI
Personalized extended interval dosing of natalizumab in MS : A prospective multicenter trial
Zoé L.E. van Kempen,E.L.J. Hoogervorst,Mike P. Wattjes,Mike P. Wattjes,N. F. Kalkers,Jop P. Mostert,Birgit I. Lissenberg-Witte,Annick de Vries,Anja ten Brinke,Bob W. van Oosten,Frederik Barkhof,Charlotte E. Teunissen,Bernard M. J. Uitdehaag,Theo Rispens,Joep Killestein +14 more
TL;DR: This study provides Class IV evidence that personalized extended interval dosing of natalizumab does not result in recurrence of disease activity in stable patients with RRMS.
References
More filters
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more
TL;DR: These revisions simplify the McDonald Criteria, preserve their diagnostic sensitivity and specificity, address their applicability across populations, and may allow earlier diagnosis and more uniform and widespread use.
Journal ArticleDOI
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Chris H. Polman,Stephen C. Reingold,Gilles Edan,Massimo Filippi,Hans-Peter Hartung,Ludwig Kappos,Fred D. Lublin,Luanne M. Metz,Henry F. McFarland,Paul O'Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Brian G. Weinshenker,Jerry S. Wolinsky +13 more
TL;DR: New evidence and consensus now strengthen the role of these criteria in the multiple sclerosis diagnostic workup to demonstrate dissemination of lesions in time, to clarify the use of spinal cord lesions, and to simplify diagnosis of primary progressive disease.
Journal ArticleDOI
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
Chris H. Polman,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,David Miller,J. Theodore Phillips,Fred D. Lublin,Gavin Giovannoni,A Wajgt,Martin Toal,F Lynn,Michael Panzara,Alfred Sandrock +12 more
TL;DR: Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.
Journal ArticleDOI
Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.
Ted Yednock,Catherine Cannon,Lawrence C. Fritz,Francisco Sánchez-Madrid,Lawrence Steinman,Nathan Karin +5 more
TL;DR: In vitro adhesion assay on tissue sections found that lymphocytes and monocytes bound selectively to inflamed EAE brain vessels, and therapies designed to interfere with α4βl integrin may be useful in treating inflammatory diseases of the central nervous system, such as multiple sclerosis.
Journal ArticleDOI
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
David Miller,Omar Khan,William A. Sheremata,Lance D Blumhardt,George P.A. Rice,Michele A Libonati,Allison J Willmer-Hulme,Catherine M. Dalton,Katherine A. Miszkiel,Paul O'Connor +9 more
TL;DR: In a placebo-controlled trial, treatment with natalizumab led to fewer inflammatory brain lesions and fewer relapses over a six-month period in patients with relapsing multiple sclerosis.